Axsome Shareholders Equity Per Share from 2010 to 2024

AXSM Stock  USD 73.08  1.98  2.78%   
Axsome Therapeutics Shareholders Equity Per Share yearly trend continues to be very stable with very little volatility. Shareholders Equity Per Share is likely to grow to 4.41 this year. During the period from 2010 to 2024, Axsome Therapeutics Shareholders Equity Per Share quarterly data regression pattern had sample variance of  17.25 and median of (0.25). View All Fundamentals
 
Shareholders Equity Per Share  
First Reported
2010-12-31
Previous Quarter
4.20420713
Current Value
4.41
Quarterly Volatility
4.15387451
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome main balance sheet or income statement drivers, such as Interest Expense of 6.8 M, Selling General Administrative of 234 M or Other Operating Expenses of 476.2 M, as well as many exotic indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0112 or PTB Ratio of 19.88. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
  
This module can also supplement Axsome Therapeutics' financial leverage analysis and stock options assessment as well as various Axsome Therapeutics Technical models . Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Latest Axsome Therapeutics' Shareholders Equity Per Share Growth Pattern

Below is the plot of the Shareholders Equity Per Share of Axsome Therapeutics over the last few years. It is Axsome Therapeutics' Shareholders Equity Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Shareholders Equity Per Share10 Years Trend
Very volatile
   Shareholders Equity Per Share   
       Timeline  

Axsome Shareholders Equity Per Share Regression Statistics

Arithmetic Mean(1.64)
Geometric Mean1.41
Coefficient Of Variation(253.83)
Mean Deviation3.14
Median(0.25)
Standard Deviation4.15
Sample Variance17.25
Range15.2876
R-Value(0)
Mean Square Error18.58
R-Squared0.000011
Significance0.99
Slope(0)
Total Sum of Squares241.57

Axsome Shareholders Equity Per Share History

2024 4.41
2023 4.2
2022 2.69
2021 -10.88
2020 -7.49
2019 -5.17
2018 -4.0

About Axsome Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Axsome Therapeutics income statement, its balance sheet, and the statement of cash flows. Axsome Therapeutics investors use historical funamental indicators, such as Axsome Therapeutics's Shareholders Equity Per Share, to determine how well the company is positioned to perform in the future. Although Axsome Therapeutics investors may use each financial statement separately, they are all related. The changes in Axsome Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Axsome Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Axsome Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Axsome Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Shareholders Equity Per Share 4.20  4.41 

Axsome Therapeutics Investors Sentiment

The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.

Pair Trading with Axsome Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Axsome Stock

  0.75ERNA Eterna TherapeuticsPairCorr
  0.72OPT OptheaPairCorr
  0.65A Agilent Technologies Earnings Call This WeekPairCorr
  0.65DYAI Dyadic International Financial Report 8th of May 2024 PairCorr
  0.62IQV IQVIA Holdings Financial Report 25th of April 2024 PairCorr
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Axsome Stock analysis

When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.27)
Revenue Per Share
5.957
Quarterly Revenue Growth
1.935
Return On Assets
(0.25)
Return On Equity
(1.59)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.